VERTAVIS
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VERTAVIS (VERTAVIS).
Vertavis is an inhibitor of acetylcholinesterase, increasing acetylcholine levels at cholinergic synapses.
| Metabolism | Primarily hydrolyzed by plasma esterases; minor hepatic metabolism via CYP450 enzymes. |
| Excretion | Approximately 70% of the dose is excreted renally as unchanged drug and 30% via biliary/fecal routes as metabolites. |
| Half-life | Terminal elimination half-life is 39–58 hours (mean 49 hours), supporting once-daily dosing. Steady state is achieved after 7–10 days. |
| Protein binding | Approximately 99% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution is 0.4–0.6 L/kg (approx 30–50 L in adults), indicating distribution primarily into extracellular fluid. |
| Bioavailability | Oral bioavailability is approximately 50% (range 30–70%) with food reducing rate but not extent of absorption. |
| Onset of Action | Oral: Clinical effect (reduction in pulmonary arterial pressure) observed within 2–4 weeks of initiating therapy. |
| Duration of Action | Duration of therapeutic effect is 24 hours with once-daily dosing; sustained hemodynamic improvements noted with chronic therapy. |
| Molecular Weight | 334.33 |
5 mg orally three times daily. May be increased to 10 mg three times daily if tolerated.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (eGFR <30 mL/min/1.73 m²), use is not recommended. |
| Liver impairment | Not recommended for use in patients with moderate to severe hepatic impairment (Child-Pugh class B or C). No data available. |
| Pediatric use | Safety and efficacy not established; no recommended dose. |
| Geriatric use | No specific dose adjustment; use with caution due to potential increased sensitivity and comorbidities. |
| 1st trimester | Avoid due to potential teratogenicity; animal studies have shown adverse effects. |
| 2nd trimester | Use only if benefit outweighs risk; may cause fetal harm. |
| 3rd trimester | Avoid near term due to risk of premature ductus arteriosus closure. |
Clinical note
Comprehensive clinical and safety monograph for VERTAVIS (VERTAVIS).
| Placental transfer | Crosses the placenta readily; detectable in fetal plasma. |
| Breastfeeding | Excreted in breast milk; not recommended while breastfeeding due to potential serious adverse effects in the infant. |
| Lactation Rating | L5 |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to vertavis or any componentSevere hepatic impairmentPregnancy (especially third trimester)
| Precautions | Cardiovascular effects (bradycardia, syncope), Gastrointestinal effects (nausea, vomiting, diarrhea), Seizures, Weight loss |
| Food/Dietary | Avoid grapefruit and grapefruit juice as they may increase ergotamine levels and risk of toxicity. Limit caffeine intake as it can exacerbate headache and interact with ergotamine. Avoid tyramine-rich foods (aged cheese, cured meats, fermented products) if migraines are triggered by tyramine. |
| Clinical Pearls |
Loading safety data…
| Teratogenic Risk | Contraindicated in pregnancy. FDA Pregnancy Category X. In animals, ribociclib (active ingredient) caused embryotoxicity, fetotoxicity, and teratogenicity at maternal exposures below human clinical exposure at 400 mg/day. First trimester: high risk of major congenital malformations; second and third trimesters: risk of fetal growth restriction and fetal death. |
| Fetal Monitoring | Pre-treatment: pregnancy testing within 7 days prior to initiation. During therapy: monitor for neutropenia (complete blood counts before each cycle, weekly for first 2 cycles, then before each cycle; dose interruptions may be required), QT prolongation (ECG before initiation and monitor electrolytes, correct hypokalemia and hypomagnesemia), hepatotoxicity (liver function tests before initiation, every 2 weeks for first 2 cycles, then monthly), and diarrhea (monitor hydration and electrolyte status). In case of accidental pregnancy exposure, monitor fetal growth and anatomy via ultrasound. |
| Fertility Effects | Based on nonclinical studies, ribociclib may impair female fertility. In male rats, testicular degeneration was observed at exposures comparable to human exposure, suggesting potential impairment of male fertility. In female rats, ovarian effects including reduced corpora lutea and follicular degeneration were observed at clinically relevant exposures. Reversibility not established. |
| Vertavis (a combination of phenobarbital, ergotamine, and belladonna alkaloids) is used for migraine and tension-type headaches. Monitor for signs of ergotism (numbness, cold extremities, muscle pain) due to ergotamine; avoid prolonged use. Phenobarbital is a controlled substance (C-IV) with abuse potential; monitor for sedation and dependence. Belladonna alkaloids cause anticholinergic effects (dry mouth, blurred vision, urinary retention). Taper dose to avoid withdrawal; avoid in patients with peripheral vascular disease, coronary artery disease, or glaucoma. |
| Patient Advice | Take Vertavis at the first sign of headache; do not exceed recommended dose. · Do not use more than 10 days per month to avoid medication-overuse headache and ergotamine toxicity. · Report symptoms of ergotism such as cold fingers or toes, numbness, tingling, or muscle pain immediately. · This medication may cause drowsiness or dizziness; avoid driving or operating machinery until you know how you react. · Avoid alcohol; it can increase sedation and ergotamine side effects. · Do not suddenly stop taking this medication; withdrawal may cause rebound headaches or seizures. |